Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: November 29, 2022

Details for Patent: 7,196,086

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Summary for Patent: 7,196,086
Title:Substituted dihydroquinazolines
Abstract: The invention relates to substituted dihydroquinazolines and to processes for their preparation and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for use as antiviral agents, in particular against cytomegalo viruses.
Inventor(s): Wunberg; Tobias (Solingen, DE), Baumeister; Judith (Wuppertal, DE), Betz; Ulrich (Wuppertal, DE), Jeske; Mario (Wuppertal, DE), Lampe; Thomas (Dusseldorf, DE), Nikolic; Susanne (Monheim, DE), Reefschlager; Jurgen (Oldenburg, DE), Schohe-Loop; Rudolf (Wuppertal, DE), Sussmeier; Frank (Wuppertal, DE), Zimmermann; Holger (Wuppertal, DE), Grosser; Rolf (Leverkusen, DE), Henninger; Kerstin (Wuppertal, DE), Hewlett; Guy (Wuppertal, DE), Keldenich; Jorg (Wuppertal, DE), Lang; Dieter (Velbert, DE), Nell; Peter (Wuppertal, DE)
Assignee: Bayer HealthCare AG (Leverkusen, DE)
Application Number:10/832,109
Patent Claim Types:
see list of patent claims
Use; Compound; Process;

Drugs Protected by US Patent 7,196,086

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,196,086

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany103 19 612May 2, 2003

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.